Artwork

Indhold leveret af Cover2 Resources and Cover 2 Resources. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Cover2 Resources and Cover 2 Resources eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
Player FM - Podcast-app
Gå offline med appen Player FM !

Ep. 237 - Understanding Purdue Pharma’s Settlement with Oklahoma

28:50
 
Del
 

Manage episode 231573995 series 1052357
Indhold leveret af Cover2 Resources and Cover 2 Resources. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Cover2 Resources and Cover 2 Resources eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
On March 26, 2019, the pharmaceutical company Purdue Pharma, a high-profile figure in the Opioid Epidemic, agreed to a $270 Million Opioid Settlement with the State of Oklahoma. The money from this settlement will fund a national addiction research and treatment center in Oklahoma. This is a unique case for several reasons. First, Oklahoma Attorney general Mike Hunter had originally sought $20 Billion in damages. Second, this is the first of more than 1,600 cases against Purdue to settle. Third, the settlement occurred one day after the Oklahoma Supreme Court denied Purdue’s request to delay the trial from its May 28th start date, and the judge had ruled that the trial could be televised. There’s a lot of subtext in a case like this, and it can be difficult to understand the intent behind each parties’ actions. With the help of legal authority Andrew Pollis, Professor at the Case Western Reserve University School of Law, we unravel the deeper meaning behind this key settlement in our struggle against the opioid crisis. Listen to today’s podcast for an expert’s perspective on Purdue Pharma’s Settlement with Oklahoma, joined by Case Western Reserve University School of Law Professor, Andrew Pollis.
  continue reading

284 episoder

Artwork
iconDel
 
Manage episode 231573995 series 1052357
Indhold leveret af Cover2 Resources and Cover 2 Resources. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Cover2 Resources and Cover 2 Resources eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
On March 26, 2019, the pharmaceutical company Purdue Pharma, a high-profile figure in the Opioid Epidemic, agreed to a $270 Million Opioid Settlement with the State of Oklahoma. The money from this settlement will fund a national addiction research and treatment center in Oklahoma. This is a unique case for several reasons. First, Oklahoma Attorney general Mike Hunter had originally sought $20 Billion in damages. Second, this is the first of more than 1,600 cases against Purdue to settle. Third, the settlement occurred one day after the Oklahoma Supreme Court denied Purdue’s request to delay the trial from its May 28th start date, and the judge had ruled that the trial could be televised. There’s a lot of subtext in a case like this, and it can be difficult to understand the intent behind each parties’ actions. With the help of legal authority Andrew Pollis, Professor at the Case Western Reserve University School of Law, we unravel the deeper meaning behind this key settlement in our struggle against the opioid crisis. Listen to today’s podcast for an expert’s perspective on Purdue Pharma’s Settlement with Oklahoma, joined by Case Western Reserve University School of Law Professor, Andrew Pollis.
  continue reading

284 episoder

Alle Folgen

×
 
Loading …

Velkommen til Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Hurtig referencevejledning